Trovagene Inc (TROV) 4.37 $TROV
Trovagene to Present at 13th Annual BIO Investor Forum
PR Newswire - Mon Oct 06, 3:30PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
TROV: 4.37 (-0.08)
Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium
PR Newswire - Wed Oct 01, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Eli Diamond, MD, Assistant Attending Neurologist at Memorial Sloan Kettering Cancer Center (MSK), presented clinical data from an ongoing study demonstrating the utility of Trovagene's precision cancer monitoring platform for the determination of oncogene mutational status in cell-free DNA obtained from a liquid biopsy. The results were presented to both treating physicians and patients at the ECD Global Alliance's Second International Medical Symposium, in collaboration with the National Institutes of Health (NIH), and expand upon clinical data presented earlier this year at the American Society of Clinical Oncology (ASCO) Annual Meeting.
TROV: 4.37 (-0.08)
Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Sep 17, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Alberto Bardelli, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Bardelli was among the first to identify mutations in the kinase genes that are associated with colorectal cancer and other malignancies. Currently, he is at the Department of Oncology, Torino Medical School, Institute for Cancer Research in Candiolo, Italy.
TROV: 4.37 (-0.08)
Can The Uptrend Continue for TrovaGene (TROV)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:49AM CDT
Can The Uptrend Continue for TrovaGene (TROV)?
TROV: 4.37 (-0.08)
Increased Earnings Estimates Seen for TrovaGene (TROV): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:47AM CDT
TrovaGene has been witnessing a positive trend in its earnings estimate front and its share price has been increasing for past 4 weeks
TROV: 4.37 (-0.08)
How TrovaGene (TROV) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:36AM CDT
TrovaGene might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
TROV: 4.37 (-0.08)
TrovaGene (TROV) Jumps: Stock Rises 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 8:18AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as the company saw its shares rise over 9% on the day.
CBPO: 54.25 (+2.14), CBM: 17.76 (-0.12), TROV: 4.37 (-0.08), GILD: 105.07 (-1.60)
Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics
PR Newswire - Tue Aug 26, 7:24AM CDT
Trovagene, Inc. (NASDAQ: TROV) presented data at the Next Generation Dx Summit; Moving Assays to the Clinic with an oral presentation entitled "Targeted Detection and Monitoring of Cell Free Tumor DNA in Urine." In this presentation Trovagene reported the analytical component of its Precision Cancer Monitoring (PCM) platform and results from several studies demonstrating high clinical sensitivity for the detection of tumor DNA mutations from urine samples of cancer patients. The PCM platform uses a proprietary urinary DNA extraction process and mutant tumor DNA enrichment methodologies coupled to next generation sequencing and proprietary bio-informatic analyses. The PCM platform enables translational studies for the demonstration of high clinical sensitivity, quantitative assessment of mutational copy levels and subsequent utility for urinary-based cell-free tumor DNA diagnostics.
TROV: 4.37 (-0.08)
Clinical Results Presented for Trovagene's Urine-Based High-Risk HPV Assay.
PR Newswire - Mon Aug 25, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical intraepithelial neoplasia (CIN2/3). Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing.
TROV: 4.37 (-0.08)
Can the Rally in TrovaGene (TROV) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 7:32AM CDT
Can the Rally in TrovaGene (TROV) Shares Continue?
TROV: 4.37 (-0.08)
Trovagene Provides Update on Its Urine-Based HPV Test
PR Newswire - Wed Aug 20, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus (IPV) conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus (HPV). The IPV conference is scheduled to take place in Seattle from August 21st to 25th. Additionally, a new U.S. patent was issued earlier this year for Trovagene's non-invasive HPV assay, and the Company continues to pursue its global partnering strategy to commercialize this novel technology.
TROV: 4.37 (-0.08)
TrovaGene (TROV) Worth Watching: Stock Rises 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:39AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as its shares rose almost 9% on the day.
CBPO: 54.25 (+2.14), CBM: 17.76 (-0.12), TROV: 4.37 (-0.08)
TrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 9:52AM CDT
TrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy?
TROV: 4.37 (-0.08)
Leader in Targeted Drug Development, Peter Hirth, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Tue Aug 12, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K. Peter Hirth, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Hirth is an industry leader and innovator with over 30 years of biotechnology and pharmaceutical discovery and development experience. A pioneer in the field of personalized medicine, Dr. Hirth led the organizations that developed both Sutent® and Zelboraf®; two successful targeted cancer therapeutics.
TROV: 4.37 (-0.08)
Trovagene, Inc. Announces Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 3:05PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and six months ended June 30, 2014.
TROV: 4.37 (-0.08)
Trovagene Schedules Release of Second Quarter 2014 Financial Results and Investor Conference Call
PR Newswire - Wed Jul 30, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the second quarter and the six months ended June 30, 2014 on Thursday, August 7, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
TROV: 4.37 (-0.08)
Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance
PR Newswire - Tue Jul 01, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV) today announced that it has secured an unrestricted debt facility in the amount of $15 million from Silicon Valley Bank and Oxford Finance LLC. The additional capital will be used to support ongoing development and commercialization activities for the Company's precision cancer monitoring platform. As a result, Trovagene expects to report approximately $35 million in cash and cash equivalents for the quarter ended June 30, 2014.
TROV: 4.37 (-0.08)
Trovagene Enters Into a Strategic Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute
PR Newswire - Mon Jun 30, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.
TROV: 4.37 (-0.08)
Trovagene Announces Clinical Collaboration with Dana-Farber Cancer Institute
PR Newswire - Mon Jun 16, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.
TROV: 4.37 (-0.08)
Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting
PR Newswire - Tue Apr 01, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
TROV: 4.37 (-0.08)
Trovagene to Present at 13th Annual BIO Investor Forum
PR Newswire - Mon Oct 06, 3:30PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will be presenting at the 13th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 13th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
TROV: 4.37 (-0.08)
Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium
PR Newswire - Wed Oct 01, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Eli Diamond, MD, Assistant Attending Neurologist at Memorial Sloan Kettering Cancer Center (MSK), presented clinical data from an ongoing study demonstrating the utility of Trovagene's precision cancer monitoring platform for the determination of oncogene mutational status in cell-free DNA obtained from a liquid biopsy. The results were presented to both treating physicians and patients at the ECD Global Alliance's Second International Medical Symposium, in collaboration with the National Institutes of Health (NIH), and expand upon clinical data presented earlier this year at the American Society of Clinical Oncology (ASCO) Annual Meeting.
TROV: 4.37 (-0.08)
Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Wed Sep 17, 7:05AM CDT
Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Alberto Bardelli, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Bardelli was among the first to identify mutations in the kinase genes that are associated with colorectal cancer and other malignancies. Currently, he is at the Department of Oncology, Torino Medical School, Institute for Cancer Research in Candiolo, Italy.
TROV: 4.37 (-0.08)
Can The Uptrend Continue for TrovaGene (TROV)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:49AM CDT
Can The Uptrend Continue for TrovaGene (TROV)?
TROV: 4.37 (-0.08)
Increased Earnings Estimates Seen for TrovaGene (TROV): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:47AM CDT
TrovaGene has been witnessing a positive trend in its earnings estimate front and its share price has been increasing for past 4 weeks
TROV: 4.37 (-0.08)
How TrovaGene (TROV) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:36AM CDT
TrovaGene might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
TROV: 4.37 (-0.08)
TrovaGene (TROV) Jumps: Stock Rises 9.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 8:18AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as the company saw its shares rise over 9% on the day.
CBPO: 54.25 (+2.14), CBM: 17.76 (-0.12), TROV: 4.37 (-0.08), GILD: 105.07 (-1.60)
Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics
PR Newswire - Tue Aug 26, 7:24AM CDT
Trovagene, Inc. (NASDAQ: TROV) presented data at the Next Generation Dx Summit; Moving Assays to the Clinic with an oral presentation entitled "Targeted Detection and Monitoring of Cell Free Tumor DNA in Urine." In this presentation Trovagene reported the analytical component of its Precision Cancer Monitoring (PCM) platform and results from several studies demonstrating high clinical sensitivity for the detection of tumor DNA mutations from urine samples of cancer patients. The PCM platform uses a proprietary urinary DNA extraction process and mutant tumor DNA enrichment methodologies coupled to next generation sequencing and proprietary bio-informatic analyses. The PCM platform enables translational studies for the demonstration of high clinical sensitivity, quantitative assessment of mutational copy levels and subsequent utility for urinary-based cell-free tumor DNA diagnostics.
TROV: 4.37 (-0.08)
Clinical Results Presented for Trovagene's Urine-Based High-Risk HPV Assay.
PR Newswire - Mon Aug 25, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two independent clinical studies were presented at the 29th International Papillomavirus (IPV) Conference. Results from both pilot studies consistently demonstrated that the Company's urine-based assay for the detection of high-risk HPV had high sensitivity (greater than 90%) for identifying women with high grade cervical intraepithelial neoplasia (CIN2/3). Assay performance was comparable to traditional HPV testing with commercially available tests in patient-matched cervical samples. In one of these studies, urine collection has been examined to establish standardization of urine as a clinical specimen for high-risk HPV testing.
TROV: 4.37 (-0.08)
Can the Rally in TrovaGene (TROV) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 7:32AM CDT
Can the Rally in TrovaGene (TROV) Shares Continue?
TROV: 4.37 (-0.08)
Trovagene Provides Update on Its Urine-Based HPV Test
PR Newswire - Wed Aug 20, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus (IPV) conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus (HPV). The IPV conference is scheduled to take place in Seattle from August 21st to 25th. Additionally, a new U.S. patent was issued earlier this year for Trovagene's non-invasive HPV assay, and the Company continues to pursue its global partnering strategy to commercialize this novel technology.
TROV: 4.37 (-0.08)
TrovaGene (TROV) Worth Watching: Stock Rises 8.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:39AM CDT
TrovaGene, Inc. (TROV) was a big mover last session, as its shares rose almost 9% on the day.
CBPO: 54.25 (+2.14), CBM: 17.76 (-0.12), TROV: 4.37 (-0.08)
TrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 9:52AM CDT
TrovaGene (TROV) Sees Hammer Chart Pattern: Time to Buy?
TROV: 4.37 (-0.08)
Leader in Targeted Drug Development, Peter Hirth, Ph.D., Joins Trovagene's Scientific Advisory Board
PR Newswire - Tue Aug 12, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K. Peter Hirth, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Hirth is an industry leader and innovator with over 30 years of biotechnology and pharmaceutical discovery and development experience. A pioneer in the field of personalized medicine, Dr. Hirth led the organizations that developed both Sutent® and Zelboraf®; two successful targeted cancer therapeutics.
TROV: 4.37 (-0.08)
Trovagene, Inc. Announces Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 3:05PM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months and six months ended June 30, 2014.
TROV: 4.37 (-0.08)
Trovagene Schedules Release of Second Quarter 2014 Financial Results and Investor Conference Call
PR Newswire - Wed Jul 30, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the second quarter and the six months ended June 30, 2014 on Thursday, August 7, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time).
TROV: 4.37 (-0.08)
Trovagene Secures $15 Million in Debt Financing From Silicon Valley Bank and Oxford Finance
PR Newswire - Tue Jul 01, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV) today announced that it has secured an unrestricted debt facility in the amount of $15 million from Silicon Valley Bank and Oxford Finance LLC. The additional capital will be used to support ongoing development and commercialization activities for the Company's precision cancer monitoring platform. As a result, Trovagene expects to report approximately $35 million in cash and cash equivalents for the quarter ended June 30, 2014.
TROV: 4.37 (-0.08)
Trovagene Enters Into a Strategic Alliance with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute
PR Newswire - Mon Jun 30, 7:05AM CDT
Trovagene, Inc. (NASDAQ: TROV), the Robert H. Lurie Comprehensive Cancer Center of Northwestern University (Lurie Cancer Center) and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) have entered into a strategic partnership to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.
TROV: 4.37 (-0.08)
Trovagene Announces Clinical Collaboration with Dana-Farber Cancer Institute
PR Newswire - Mon Jun 16, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV) today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.
TROV: 4.37 (-0.08)
Trovagene Announces Clinical Data Presentation for Its Oncogene Mutation Monitoring Platform at the American Association for Cancer Research Annual Meeting
PR Newswire - Tue Apr 01, 7:00AM CDT
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California.
TROV: 4.37 (-0.08)
